Please assess the completion status of the following clinical trial:

Trial Title: A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-1 infected male or female adults at least 18 years of age. Women capable of becoming pregnant must use appropriate contraception during the study (as defined by the protocol);~* HIV-1 infection with a screening plasma HIV-1 RNA greater than or equal to 1000copies/mL;~* CD4+ cell count greater than or equal to 200cells/mm3 (or higher as local guidelines dictate);~* ART-naive (less than or equal to 10 days of prior therapy with any antiretroviral agent). Any previous exposure to an HIV integrase inhibitor other than GSK1349572 will be exclusionary.~* No evidence of viral resistance to any antiretroviral drug indicative of primary transmitted resistance at screening;~* Able to understand and comply with protocol requirements;~* Able to provide written informed consent prior to screening;~* French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.~Note: Subjects starting abacavir as part of the NRTI backbone must have been screened and be negative for the HLA-B\*5701 allele.~Exclusion Criteria:~* Any pre-existing or serious mental or physical disorder which could compromise ability to comply with the protocol or compromise subject safety;~* Women who are pregnant or breastfeeding;~* An active AIDS-defining condition at the screening visit;~* Previous participation in an experimental drug and/or vaccine trial(s) within 30 days or 5 half-lives;~* History of clinically relevant pancreatitis or hepatitis within the previous 6 months, including HBsAg positive result. Asymptomatic HCV infection will not be exclusionary, however subject who will require HCV therapy during the trial should be excluded. Any subject with a history of liver cirrhosis with or without hepatitis viral co-infection will be excluded.~* Any condition which could interfere with the absorption, distribution, metabolism or excretion of the drug;~* Any acute or Grade 4 laboratory abnormality at screening;~* History of upper gastrointestinal bleed and/or subjects with active peptic ulcer disease;~* Estimated creatinine clearance \<50 mL/min;~* Alanine aminotransferase (ALT) greater than or equal to 5 times ULN;~* Alanine aminotransferase (ALT) greater than or equal to 3xULN and bilirubin greater than or equal to 1.5xULN (with \>35% direct bilirubin);~* Lipase greater than or equal to 3xULN;~* Hemoglobin \< 100 g/L(10 g/dL);~* History of allergy to the study drugs or their components or drugs of their class;~* Treatment with radiation therapy, cytotoxic chemotherapeutic agents, any agents with activity against HIV-1 or immunomodulators within 28 days prior to screening;~* Treatment with an HIV-1 immunotherapeutic vaccine within 90 days prior to screening;~* History of protocol-defined cardiac diseases;~* Personal or family history of prolonged QT syndrome;~* Any clinically significant finding, as specified in the protocol, on electrocardiograph (ECG);~* Significant blood loss in excess of 500 mL within a 56 day period prior to screening visit;~* Immunization within 30 days prior to first dose of investigational product;~* French subjects: The subject has participated in any study using an investigational drug during the previous 60 days or 5 half-lives, or twice the duration of the biological effect of the experimental drug or vaccine - whichever is longer, prior to screening for the study or the subject will participate simultaneously in another clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 10 mg GSK1349572 (Type: EXPERIMENTAL): subjects will receive GSK1349572 10mg once daily blinded to dose
- 25mg GSK1349572 (Type: EXPERIMENTAL): subjects will receive GSK1349572 25mg once daily blinded to dose
- 50mg GSK1349572 (Type: EXPERIMENTAL): subjects will receive GSK1349572 50mg once daily blinded to dose
- efavirenz control (Type: OTHER): efavirenz will serve as the internal control arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete